Cáncer De Cuello Uterino: Causas, Diagnóstico Y Tratamiento pressperu.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressperu.com Daily Mail and Mail on Sunday newspapers.
Press release content from Accesswire. The AP news staff was not involved in its creation.
Abivax Hosting Key Opinion Leader Webinar on ABX464 for the Treatment of Ulcerative Colitis
April 19, 2021 GMT
The Webinar takes place on Tuesday, April 20, 2021 at 7:30am EDT (1:30pm CEST)PARIS, FRANCE / ACCESSWIRE / April 19, 2021 / Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that .
The Webinar takes place on Tuesday, April 20, 2021 at 7:30am EDT (1:30pm CEST)PARIS, FRANCE / ACCESSWIRE / April 19, 2021 / Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that .
The Webinar takes place on Tuesday, April 20, 2021 at 7:30am EDT (1:30pm CEST)
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Ehave Prepares to Launch Ketamine Clinical Trials Using Brain Scientific’s Brain Mapping Technology
EhaveApril 16, 2021 GMT
MIAMI, April 16, 2021 (GLOBE NEWSWIRE) Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today plans to launch brain mapping ketamine clinical trials using Brain Scientific technology later this year. The clinical trial will establish the statistical correlation between the ketamine treatment and patient improvement from the disorders.
The trial, which is designed to enroll 35 patients, is expected to start in the second half of 2021. Ehave is currently completing the necessary preclinical studies necessary to begin enrolling patients in the trial. The average drop out ratio of clinical trials is around 15 % and Ehave will need at least 25-30 patients’ egg data to es
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
New England Journal of Medicine publishes exploratory study showing signals of positive .
COMPASS Pathfinder Ltd.April 15, 2021 GMT
London, UK, April 15, 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed a study published in the New England Journal of Medicine (NEJM) yesterday, which showed signals of positive activity in COMP360 psilocybin compared with the standard antidepressant escitalopram, for major depressive disorder (MDD).
ADVERTISEMENT
The study was designed and conducted by a research team at Imperial College London, using COMPASS’s COMP360 psilocybin.
Press release content from Accesswire. The AP news staff was not involved in its creation.
PrestoDoctor to Offer On-site Evaluations at Pennsylvania Cannabis Festival April 17-18
April 15, 2021 GMT
MESQUITE, NV / ACCESSWIRE / April 15, 2021 / Cannabis Sativa, Inc. (OTCQB:CBDS) is proud to announce that PrestoDoctor will offer on-site evaluations at the Pennsylvania Cannabis Festival Freedom Through Growth live event on April 17 & 18 at .
MESQUITE, NV / ACCESSWIRE / April 15, 2021 / Cannabis Sativa, Inc. (OTCQB:CBDS) is proud to announce that PrestoDoctor will offer on-site evaluations at the Pennsylvania Cannabis Festival Freedom Through Growth live event on April 17 & 18 at .
MESQUITE, NV / ACCESSWIRE / April 15, 2021 / Cannabis Sativa, Inc. (OTCQB:CBDS) is proud to announce that PrestoDoctor will offer on-site evaluations at the Pennsylvania Cannabis Festival “Freedom Through Growth” live event on April 17 & 18 at Renninger’s Farmers Market in Kutztown, Pennsylvania.